| As we mark summer holidays in Canada and the U.S., we reflect on a powerful truth: the next decade of biotech won’t be won by the best biologics alone—but by the systems that deliver them.
From cancer immunotherapies to long-acting antibodies for infectious disease, science has outpaced infrastructure. Cold chains, frequent dosing, and complex manufacturing still limit who benefits and how widely.
At Eyam Health, we’ve built Gemini to change that.
Strategic Momentum
This quarter marks a turning point. Through new partnerships, grant funding, and scientific progress, Eyam is executing on its platform vision across species, sectors, and geographies.
Gemini + MMV: A New Era in Malaria Prevention
Eyam has entered into a long-term partnership with Medicines for Malaria Venture (MMV), the world’s leading nonprofit focused on malaria eradication. Together, we aim to create a globally deployable malaria prevention monoclonal antibody—backed by Gemini’s single-dose, ambient-temperature-stable delivery.
This milestone advances a new class of malaria-preventing biologics, aligning technological innovation with real-world access in endemic regions.
Veterinary Biologics: Partnerships Advancing
We are finalizing agreements with global animal health pharmas for Gemini-enabled vaccines and antibody therapies targeting livestock and companion animals.
Gemini’s cold-chain independence and long-acting expression are especially powerful in high-throughput veterinary settings, where scale and durability are critical.
New Grants Awarded
Eyam has been awarded new grants to support preclinical development and internal R&D. This non-dilutive funding allows us to pursue exploratory programs in chronic disease and oncology—while preserving strategic capital for scale-up initiatives.
Large Animal Studies Launch in Q3
We’re initiating studies across three large-animal models:
- Non-Human Primates (NHPs): Antibody expression durability
- Canine: Therapeutics for chronic disease
- Porcine: Dose and safety validation
These studies follow strong murine and in vitro data, and will play a central role in validating Gemini’s readiness for broader deployment.
Platform Strategy: Gemini as Infrastructure
Gemini is a delivery engine for next-gen biologics. Its core advantages:
- Ambient-stable: No cold chain
- Self-amplifying: Durable expression from a single dose
- LNP-free: Simpler, safer production
- Dual-format: Works as saDNA (Gemini-D) or saRNA (Gemini-R)
- Low-cost: Produces biologics at dramatically reduced COGS
From human health to veterinary care, Gemini unlocks scale where traditional biologics fall short.
Looking Ahead: H2 2025 Milestones
Key initiatives underway:
- Q3: Large animal studies begin
- Q4: Initial data from partner programs
- Early 2026: Additional licensing agreements and milestone progression
In parallel, our internal programs in infectious disease, oncology, and chronic illness continue to advance toward partnership or clinical readiness.
We’re Building Biotech That Works Everywhere
At Eyam, we believe delivery is the most important unsolved challenge in biologics. With Gemini, we’re not just solving it—we’re reimagining what biologics can do when designed for the real world. |
